Kim MK

References (16)

Title : Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models - Kim_2017_Arch.Pharm.Res_40_268
Author(s) : Kim MK , Chae YN , Ahn GJ , Shin CY , Choi SH , Yang EK , Sohn YS , Son MH
Ref : Arch Pharm Res , 40 :268 , 2017
Abstract : Dipeptidyl peptidase 4 (DPP4) is an adipokine that interrupts insulin signaling. The resulting insulin resistance exacerbates hepatic steatosis. We previously reported that the novel DPP4 inhibitor evogliptin improves insulin resistance. This study aimed to verify the therapeutic potential of evogliptin for fatty liver. Evogliptin treatment was initiated simultaneously with a high-fat diet (HFD) feeding in normal mice and in a post-24 week HFD-fed rats. In a prevention study, insulin sensitivity was preserved in evogliptin-treated mice after a 16-week treatment. Overall plasma lipid levels stayed lower and hepatic lipid accumulation was drastically suppressed by evogliptin treatment. Evogliptin reduced hepatic expression of Srebf1, a key transcriptional factor for lipogenesis. Additionally, DPP4 inhibitor-treated mice showed less weight gain. In a treatment study, after evogliptin treatment for 14 weeks in pre-established HFD-fed obese rats, weight loss was marginal, while hepatic lipid accumulation and liver damage assessed by measuring plasma aminotransferase levels were completely resolved, suggesting weight loss-independent beneficial effects on fatty liver. Moreover, reduction in plasma non-esterified fatty acids supported the improvement of insulin resistance by evogliptin treatment. Conclusively, our findings suggest that evogliptin treatment ameliorates fatty liver by increasing insulin sensitivity and suppressing lipogenesis.
ESTHER : Kim_2017_Arch.Pharm.Res_40_268
PubMedSearch : Kim_2017_Arch.Pharm.Res_40_268
PubMedID: 27885461

Title : Unique binding mode of Evogliptin with human dipeptidyl peptidase IV - Lee_2017_Biochem.Biophys.Res.Commun_494_452
Author(s) : Lee HK , Kim MK , Kim HD , Kim HJ , Kim JW , Lee JO , Kim CW , Kim EE
Ref : Biochemical & Biophysical Research Communications , 494 :452 , 2017
Abstract : Evogliptin ((R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl) piperazine-2-one)) is a highly potent selective inhibitor of dipeptidyl peptidase IV (DPP4) that was approved for the treatment of type 2 diabetes in South Korea. In this study, we report the crystal structures of Evogliptin, DA-12166, and DA-12228 (S,R diastereomer of Evogliptin) complexed to human DPP4. Analysis of both the structures and inhibitory activities suggests that the binding of the trifluorophenyl moiety in the S1 pocket and the piperazine-2-one moiety have hydrophobic interactions with Phe357 in the S2 extensive subsite, and that the multiple hydrogen bonds made by the (R)-beta-amine group in the S2 pocket and the contacts made by the (R)-tert-butyl group with Arg125 contribute to the high potency observed for Evogliptin.
ESTHER : Lee_2017_Biochem.Biophys.Res.Commun_494_452
PubMedSearch : Lee_2017_Biochem.Biophys.Res.Commun_494_452
PubMedID: 29061303
Gene_locus related to this paper: human-DPP4

Title : Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers - Jang_2017_Drug.Des.Devel.Ther_11_705
Author(s) : Jang K , Kim MK , Oh J , Lee S , Cho JY , Yu KS , Choi TK , Lee SH , Lim KS
Ref : Drug Des Devel Ther , 11 :705 , 2017
Abstract : PURPOSE: Oseltamivir is widely used in the treatment and prophylaxis of influenza A and B viral infections. It is ingested as an oral prodrug that is rapidly metabolized by carboxylesterase 1 (CES1) to its active form, oseltamivir carboxylate. Dexamethasone is also used in the treatment of acute respiratory distress syndrome, a severe complication of influenza; however, its influence on the pharmacokinetics (PK) of oseltamivir is controversial. The aim of this study was to investigate the effects of coadministering oseltamivir and dexamethasone on the PK of oseltamivir in healthy volunteers.
METHODS: An open-label, two-period, one-sequence, multiple-dose study was conducted in 19 healthy male volunteers. Oseltamivir (75 mg) was orally administered on Day 1 and Day 8, and dexamethasone (1.5 mg) was administered once daily from Day 3 to Day 8. Serial blood and urine samples were collected for PK analysis of oseltamivir and oseltamivir carboxylate on Day 1 and Day 8. Oseltamivir and oseltamivir carboxylate concentrations in plasma and urine were determined using liquid chromatography-tandem mass spectrometry.
RESULTS: Area under the plasma concentration-time curve (AUC) of oseltamivir and oseltamivir carboxylate decreased after dexamethasone treatment for 6 days. The geometric mean ratio (90% confidence interval) of the metabolic ratio (oseltamivir carboxylate AUC0-48h/oseltamivir AUC0-48h) was 0.92 (0.87-0.97). The amount of unchanged oseltamivir excreted in urine increased by 14% after dexamethasone treatments. CONCLUSION: Coadministration of dexamethasone with oseltamivir slightly decreased systemic exposure to oseltamivir and oseltamivir carboxylate in healthy volunteers. This result suggests that CES1 is inhibited by dexamethasone in humans. However, coadministration of oseltamivir and dexamethasone did not appear to have a clinically relevant effect on the PK of oseltamivir; based on these results, dexamethasone can be coadministered with oseltamivir.
ESTHER : Jang_2017_Drug.Des.Devel.Ther_11_705
PubMedSearch : Jang_2017_Drug.Des.Devel.Ther_11_705
PubMedID: 28331290

Title : Flavisolibacter tropicus sp. nov., isolated from tropical soil - Lee_2016_Int.J.Syst.Evol.Microbiol_66_3413
Author(s) : Lee JJ , Kang MS , Kim GS , Lee CS , Lim S , Lee J , Roh SH , Kang H , Ha JM , Bae S , Jung HY , Kim MK
Ref : Int J Syst Evol Microbiol , 66 :3413 , 2016
Abstract : A Gram-stain-negative, non-motile, deep yellow, rod-shaped bacterium, designated strain LCS9T, was isolated from a soil sample at the tropical zone within the Ecorium of the National Institute of Ecology in Seocheon, central-western Korea. 16S rRNA gene sequence analysis showed that strain LCS9T clustered with members of the genus Flavisolibacter of the family Chitinophagaceae, phylum Bacteroidetes. Sequence similarities between strain LCS9T and the type strains of the genus Flavisolibacter ranged from 94.6 to 94.9 %. Strain LCS9T grew at 10-37 degrees C (optimum, 25 degrees C) and at pH 6.0-10.0 (optimum, pH 7); was positive for catalase and oxidase; and negative for nitrate reduction and production of indole. Cells showed pigment absorbance peaks at 451 and 479 nm, and had 0.03 % survival following exposure to 3 kGy gamma radiation. Strain LCS9T had the following chemotaxonomic characteristics: the major quinone was menaquinone-7 (MK-7); the major fatty acids were iso-C15 : 0 and iso-C17 : 0 3-OH; polar lipids included phosphoatidylethanolamine, an unidentified aminophospholipid, unidentified aminolipidsand unidentified lipids. The DNA G+C content was 39.4 mol%. Based on polyphasic analysis, the type strain LCS9T (=KCTC 42070T=JCM 19972T) represents a novel species for which the name Flavisolibacter tropicus sp. nov. is proposed. Radiation resistance in the genus Flavisolibacter has not been reported to date, and so this is the first report of low-level radiation resistance of a member of the genus.
ESTHER : Lee_2016_Int.J.Syst.Evol.Microbiol_66_3413
PubMedSearch : Lee_2016_Int.J.Syst.Evol.Microbiol_66_3413
PubMedID: 27259556
Gene_locus related to this paper: 9bact-a0a172try1

Title : Cognitive-Enhancing Effect of Aronia melanocarpa Extract against Memory Impairment Induced by Scopolamine in Mice - Lee_2016_Evid.Based.Complement.Alternat.Med_2016_6145926
Author(s) : Lee HY , Weon JB , Jung YS , Kim NY , Kim MK , Ma CJ
Ref : Evid Based Complement Alternat Med , 2016 :6145926 , 2016
Abstract : Aronia melanocarpa (A. melanocarpa) berries are a fruit with a marked antioxidant effect. The objective of this study was to confirm the effect of A. melanocarpa berries extract against scopolamine-induced memory impairment in mice using the Morris water maze and passive avoidance test. Moreover, we determined a possible mechanism of the cognitive-enhancing effect involving AChE activity and BDNF and p-CREB expression in the hippocampus of mice. A. melanocarpa berries extract attenuated the learning and memory impairment induced by scopolamine in the Morris water maze (79.3 +/- 0.8 s of 200 mg/kg and 64.4 +/- 10.7 s of 400 mg/kg on day 4) and passive avoidance tests (46.0 +/- 41.1 s of 200 mg/kg and 25.6 +/- 18.7 s of 400 mg/kg). A. melanocarpa berries extract reduced the acetylcholinesterase level in the hippocampus of scopolamine-injected mice and increased BDNF and p-CREB expression in the hippocampus. The major compound, cyanidin-3-O-galactoside, also reversed memory impairment. These results showed that A. melanocarpa berries extract improved memory impairment by inhibiting AChE and increasing BDNF and p-CREB expression, and cyanidin-3-O-galactoside may be responsible for the effect of A. melanocarpa berries extract.
ESTHER : Lee_2016_Evid.Based.Complement.Alternat.Med_2016_6145926
PubMedSearch : Lee_2016_Evid.Based.Complement.Alternat.Med_2016_6145926
PubMedID: 27239211

Title : Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes - Kim_2016_Eur.J.Pharmacol_771_65
Author(s) : Kim TH , Kim MK , Cheong YH , Chae YN , Lee Y , Ka SO , Jung IH , Shin CY , Bae EJ , Son MH
Ref : European Journal of Pharmacology , 771 :65 , 2016
Abstract : Although multiple dipeptidyl peptidase 4 (DPP4) inhibitors have shown glucose-lowering effects by preserving pancreatic cells in high-fat diet (HFD)/streptozotocin (STZ)-induced diabetic mice, the hepatic role in regulation of glucose homeostasis by DPP4 inhibitors in HFD/STZ mice remains elusive. In herein study, parallel comparison of effects on the liver (expression of gluconeogenic genes and the linked signaling molecules) and pancreas (islet morphology and relative area of alpha or beta cells) in combination with glucose-lowering effects were made at the end of 2- and 10-week of evogliptin treatment in HFD/STZ mice. Significant control of hyperglycemia was observed from the second week and persisted during 10-week treatment of 0.3% evogliptin in HFD/STZ mice. This effect was accompanied by increased level of plasma glucagon-like peptide-1 and preserved pancreas islet structure. Furthermore, the hepatic increases in gluconeogenic gene expression in HFD/STZ mice was significantly reduced by evogliptin treatment, which was accompanied by the suppression of cAMP response element-binding protein (CREB) phosphorylation and expression of transducer of regulated CREB protein 2. This hepatic effect of evogliptin treatment was reproduced in 2-week study, however, pancreatic beta-cell area was not altered yet although the expression of pancreatic and duodenal homeobox protein 1 was increased. We conclude that the suppression of hepatic gluconeogenesis by evogliptin is followed by preservation of pancreatic islet, leading to remarkable and persistent glucose-lowering effect in HFD/STZ mice. Our findings provide further insight for the hepatic role in DPP4 inhibitor-mediated glucose control in diabetes.
ESTHER : Kim_2016_Eur.J.Pharmacol_771_65
PubMedSearch : Kim_2016_Eur.J.Pharmacol_771_65
PubMedID: 26621343

Title : Effects of donepezil, an acetylcholinesterase inhibitor, on neurogenesis in a rat model of vascular dementia - Kwon_2014_J.Neurol.Sci_347_66
Author(s) : Kwon KJ , Kim MK , Lee EJ , Kim JN , Choi BR , Kim SY , Cho KS , Han JS , Kim HY , Shin CY , Han SH
Ref : Journal of Neurology Sci , 347 :66 , 2014
Abstract : Vascular dementia (VaD) is the second most common form of dementia caused by cerebrovascular disease. Several recent reports demonstrated that cholinergic deficits are implicated in the pathogenesis of VaD and that cholinergic therapies have shown improvement of cognitive function in patients with VaD. However, the precise mechanisms by which donepezil achieves its effects on VaD are not fully understood. Donepezil hydrochloride is an acetylcholinesterase inhibitor (AChEI) currently used for the symptomatic treatment of Alzheimer's disease (AD). Several lines of evidence have demonstrated that AChEIs such as donepezil promote neurogenesis in the central nervous system. We investigated whether donepezil regulated hippocampal neurogenesis after bilateral common carotid artery occlusion (BCCAO) in rats, a commonly used animal model of VaD. To evaluate the effect of donepezil on neurogenesis, we orally treated rats with donepezil (10mg/kg) once a day for 3weeks, and injected BrdU over the same 3-week period to label newborn cells. The doses of donepezil that we used have been reported to activate cholinergic activity in rats. After 3weeks, a water maze task was performed on these rats to test spatial learning, and a subsequent histopathological evaluation was conducted. Donepezil improved memory impairment and increased the number of BrdU-positive cells in the dentate gyrus (DG) of BCCAO animals. These results indicated that donepezil improves cognitive function and enhances the survival of newborn neurons in the DG in our animal model of VaD, possibly by enhancing the expression of choline acetyltransferase and brain-derived neurotropic factor.
ESTHER : Kwon_2014_J.Neurol.Sci_347_66
PubMedSearch : Kwon_2014_J.Neurol.Sci_347_66
PubMedID: 25266713

Title : Spirosoma radiotolerans sp. nov., a gamma-radiation-resistant bacterium isolated from gamma ray-irradiated soil - Lee_2014_Curr.Microbiol_69_286
Author(s) : Lee JJ , Srinivasan S , Lim S , Joe M , Im S , Bae SI , Park KR , Han JH , Park SH , Joo BM , Park SJ , Kim MK
Ref : Curr Microbiol , 69 :286 , 2014
Abstract : A Gram-negative, short-rod-shaped bacterial strain with gliding motility, designated as DG5A(T), was isolated from a rice field soil in South Korea. Phylogenic analysis using 16S rRNA gene sequence of the new isolate showed that strain DG5A(T) belong to the genus Spirosoma in the family Spirosomaceae, and the highest sequence similarities were 95.5 % with Spirosoma linguale DSM 74(T), 93.4 % with Spirosoma rigui WPCB118(T), 92.8 % with Spirosoma luteum SPM-10(T), 92.7 % with Spirosoma spitsbergense SPM-9(T), and 91.9 % with Spirosoma panaciterrae Gsoil 1519(T). Strain DG5A(T) revealed resistance to gamma and UV radiation. Chemotaxonomic data showed that the most abundant fatty acids were summed feature C(16:1) omega7c/C(16:1) omega6c (36.90 %), C(16:1) omega5c (29.55 %), and iso-C(15:0) (14.78 %), and the major polar lipid was phosphatidylethanolamine (PE). The DNA G+C content of strain DG5A(T) was 49.1 mol%. Together, the phenotypic, phylogenetic, and chemotaxonomic data supported that strain DG5A(T) presents a novel species of the genus Spirosoma, for which the name Spirosoma radiotolerans sp. nov., is proposed. The type strain is DG5A(T) (=KCTC 32455(T) = JCM19447(T)).
ESTHER : Lee_2014_Curr.Microbiol_69_286
PubMedSearch : Lee_2014_Curr.Microbiol_69_286
PubMedID: 24748440
Gene_locus related to this paper: 9bact-a0a0e3v606 , 9bact-a0a0e3zrk0 , 9bact-a0a0e3zva1 , 9bact-a0a0e3zvi6 , 9bact-a0a0e3zsw1 , 9bact-a0a0e3vah2 , 9bact-a0a0e4a055

Title : Structural basis for the beta-lactamase activity of EstU1, a family VIII carboxylesterase - Cha_2013_Proteins_81_2045
Author(s) : Cha SS , An YJ , Jeong CS , Kim MK , Jeon JH , Lee CM , Lee HS , Kang SG , Lee JH
Ref : Proteins , 81 :2045 , 2013
Abstract : EstU1 is a unique family VIII carboxylesterase that displays hydrolytic activity toward the amide bond of clinically used beta-lactam antibiotics as well as the ester bond of p-nitrophenyl esters. EstU1 assumes a beta-lactamase-like modular architecture and contains the residues Ser100, Lys103, and Tyr218, which correspond to the three catalytic residues (Ser64, Lys67, and Tyr150, respectively) of class C beta-lactamases. The structure of the EstU1/cephalothin complex demonstrates that the active site of EstU1 is not ideally tailored to perform an efficient deacylation reaction during the hydrolysis of beta-lactam antibiotics. This result explains the weak beta-lactamase activity of EstU1 compared with class C beta-lactamases. Finally, structural and sequential comparison of EstU1 with other family VIII carboxylesterases elucidates an operative molecular strategy used by family VIII carboxylesterases to extend their substrate spectrum. Proteins 2013; 81:2045-2051. (c) 2013 Wiley Periodicals, Inc.
ESTHER : Cha_2013_Proteins_81_2045
PubMedSearch : Cha_2013_Proteins_81_2045
PubMedID: 23737193

Title : Cloning and identification of a new group esterase (Est5S) from noncultured rumen bacterium - Kim_2012_J.Microbiol.Biotechnol_22_1044
Author(s) : Kim MK , Kang TH , Kim J , Kim H , Yun HD
Ref : J Microbiol Biotechnol , 22 :1044 , 2012
Abstract : The gene encoding an esterase enzyme was cloned from a metagenomic library of cow rumen bacteria. The esterase gene (est5S) was 1,026 bp in length, encoding a protein of 366 amino acid residues with a calculated molecular mass of 40,168 Da. The molecular mass of the enzyme was estimated to be 40,000 Da. The Est5S protein contains the Gly-X-Ser-X-Gly motif found in most bacterial and eukaryotic serine hydrolases. However, the Asp or Glu necessary for the catalytic triad [Ser-Asp-(Glu)-His] was not present, indicating Est5S represents a novel member of the GHSQG family of esterolytic enzymes. BlastP in the NCBI database analysis of Est5S revealed homology to hypothetical proteins and it had no homology to previous known lipases and esterases. Est5S was optimally active at pH 7.0 and 40 degrees C. Among the p-nitrophenyl acylesters tested, high enzymatic activities were observed on the short-chain p-nitrophenyl acylesters, such as p-nitrophenyl acetate, etc. The conserved serine residue (Ser190) was shown to be important for Est5S activity. The primers that amplified the est5S gene did not show any relative band with 49 species of culturable rumen bacteria. This implies that a new group esterase gene, est5S, may have come from a noncultured cow rumen bacterium.
ESTHER : Kim_2012_J.Microbiol.Biotechnol_22_1044
PubMedSearch : Kim_2012_J.Microbiol.Biotechnol_22_1044
PubMedID: 22713979
Gene_locus related to this paper: 9bact-q0gpb3

Title : DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes - Kim_2012_Life.Sci_90_21
Author(s) : Kim MK , Chae YN , Kim HD , Yang EK , Cho EJ , Choi SH , Cheong YH , Kim HS , Kim HJ , Jo YW , Son MH , Kim SH , Shin CY
Ref : Life Sciences , 90 :21 , 2012
Abstract : AIM: To characterize the pharmacodynamic profile of DA-1229, a novel dipeptidyl peptidase (DPP) 4 inhibitor. MAIN
METHODS: Enzyme inhibition assays against DPP4, DPP8 and DPP9. Antidiabetic effects of DA-1229 in HF-DIO mice and young db/db mice. KEY FINDINGS: DA-1229 was shown to potently inhibit the DPP4 enzyme in human and murine soluble forms and the human membrane-bound form with IC(50) values of 0.98, 3.59 and 1.26 nM, respectively. As a reversible and competitive inhibitor, DA-1229 was more selective to human DPP4 (6000-fold) than to human DPP8 and DPP9. DA-1229 (0.1-3mg/kg) dose-dependently inhibited plasma DPP4 activity, leading to increased levels of plasma GLP-1 and insulin, and thereby lowering blood glucose levels in mice. In high fat diet-fed (HF) mice, a single oral dose of 100mg/kg of DA-1229 reduced plasma DPP4 activity by over 80% during a 24h period. Long-term treatment with DA-1229 for 8 weeks revealed significant improvements in glucose intolerance and insulin resistance, accompanied by significant body weight reduction. However, it remains unclear whether there is a direct causal relationship between DPP4 inhibition and body weight reduction. In young db/db mice, the DA-1229 treatment significantly reduced blood glucose excursions for the first 2 weeks, resulting in significantly lower levels of HbA1c at the end of the study. Furthermore, the pancreatic insulin content of the treatment group was significantly higher than that of the db/db control. SIGNIFICANCE: DA-1229 as a novel and selective DPP4 inhibitor improves the insulin sensitivity in HF mice and delays the onset of diabetes in young db/db mice.
ESTHER : Kim_2012_Life.Sci_90_21
PubMedSearch : Kim_2012_Life.Sci_90_21
PubMedID: 22056373

Title : Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes - Kim_2011_Bioorg.Med.Chem.Lett_21_3809
Author(s) : Kim HJ , Kwak WY , Min JP , Lee JY , Yoon TH , Kim HD , Shin CY , Kim MK , Choi SH , Kim HS , Yang EK , Cheong YH , Chae YN , Park KJ , Jang JM , Choi SJ , Son MH , Kim SH , Yoo M , Lee BJ
Ref : Bioorganic & Medicinal Chemistry Lett , 21 :3809 , 2011
Abstract : A series of beta-amino amide containing substituted piperazine-2-one derivatives was synthesized and evaluated as inhibitors of dipeptidyl pepdidase-4 (DPP-4) for the treatment of type 2 diabetes. As results of intensive SAR study of the series, (R)-4-[(R)-3-amino-4-(2,4,5-trifluorophenyl)-butanoyl]-3-(t-butoxymethyl)-piperaz in-2-one (DA-1229) displayed potent DPP-4 inhibition pattern in several animal models, was selected for clinical development.
ESTHER : Kim_2011_Bioorg.Med.Chem.Lett_21_3809
PubMedSearch : Kim_2011_Bioorg.Med.Chem.Lett_21_3809
PubMedID: 21570283

Title : Complete genome sequence of Bifidobacterium longum subsp. longum KACC 91563 - Ham_2011_J.Bacteriol_193_5044
Author(s) : Ham JS , Lee T , Byun MJ , Lee KT , Kim MK , Han GS , Jeong SG , Oh MH , Kim DH , Kim H
Ref : Journal of Bacteriology , 193 :5044 , 2011
Abstract : Bifidobacterium longum strains predominate in the colonic microbiota of breast-fed infants. Here we report the complete genome sequence of B. longum subsp. longum KACC 91563, isolated from feces of neonates. A single circular chromosome of 2,385,301 bp contains 1,980 protein-coding genes, 56 tRNA genes, and 3 rRNA operons.
ESTHER : Ham_2011_J.Bacteriol_193_5044
PubMedSearch : Ham_2011_J.Bacteriol_193_5044
PubMedID: 21742881
Gene_locus related to this paper: bifln-c2gtr2

Title : Kaistella koreensis gen. nov., sp. nov., a novel member of the Chryseobacterium-Bergeyella-Riemerella branch - Kim_2004_Int.J.Syst.Evol.Microbiol_54_2319
Author(s) : Kim MK , Im WT , Shin YK , Lim JH , Kim SH , Lee BC , Park MY , Lee KY , Lee ST
Ref : Int J Syst Evol Microbiol , 54 :2319 , 2004
Abstract : Gram-negative, non-spore-forming, rod-shaped, yellow-pigmented bacteria isolated from a freshwater stream in Korea were investigated to determine their taxonomic position. Complete 16S rRNA gene sequence analysis indicated that the organisms should be placed in the Chryseobacterium-Bergeyella-Riemerella branch in the family Flavobacteriaceae. Phylogenetically, the strains were most closely related to Chryseobacterium balustinum ATCC 33487(T) and Chryseobacterium scophthalmum LMG 13028(T) (94.3 and 94.1 % 16S rRNA gene sequence similarity, respectively) and they clustered on a separate well-supported branch. The strains contained menaquinone MK-6 as the predominant respiratory quinone and showed higher G+C contents (41.7 mol%) than other species in the Chryseobacterium-Bergeyella-Riemerella branch and i-C(15 : 0) as a major fatty acid (47-52 %). The phylogenetic distances from any species with validly published names and their phenotypic properties confirmed that the strains constitute a separate species in a new genus, for which the name Kaistella koreensis gen. nov., sp. nov. is proposed (type strain Chj707(T)=KCTC 12107(T)=IAM 15050(T)).
ESTHER : Kim_2004_Int.J.Syst.Evol.Microbiol_54_2319
PubMedSearch : Kim_2004_Int.J.Syst.Evol.Microbiol_54_2319
PubMedID: 15545478
Gene_locus related to this paper: 9flao-a0a0j7j378

Title : Effect of Acanthopanax senticosus on lipoprotein lipase in 3T3-L1 adipocytes - Yang_2004_Phytother.Res_18_160
Author(s) : Yang JY , Lee KS , Kim MK , Moon SK , Kang MK , Park BH , Kim JS , Park JW
Ref : Phytother Res , 18 :160 , 2004
Abstract : The effect of Acanthopanax senticosus (AS) leaves on lipoprotein lipase (LPL) was investigated in 3T3-L1 adipocytes. A water extract of AS leaves increased the LPL activity in culture medium of adipocytes in a dose- and time-dependent manner. The AS extract contained heparin-like LPL releasing components, however, the increase of medium LPL activity was continued up until 12 h, in contrast to the rapid decline after heparin treatment. The increase of LPL mRNA was also observed after AS extract treatment, suggesting that LPL induction occurs at the transcriptional level. The AS extract could partially reverse the LPL suppression by tumour necrosis factor-alpha in 3T3-L1 adipocytes. These results of an AS extract-induced increase of LPL activity in vitro suggest the possible action of AS as a facilitator of plasma triglyceride clearance.
ESTHER : Yang_2004_Phytother.Res_18_160
PubMedSearch : Yang_2004_Phytother.Res_18_160
PubMedID: 15022170

Title : Cloning and expression of the gene encoding phospholipase A1 from Serratia sp. MK1 in Escherichia coli - Song_1999_J.Biotechnol_72_103
Author(s) : Song JK , Kim MK , Rhee JS
Ref : J Biotechnol , 72 :103 , 1999
Abstract : The gene encoding extracellular phospholipase A1 of Serratia sp. MK1 was cloned from a genomic DNA library. Formation of transparent halos on the PCY agar plates was used to identify E. coli carrying the phospholipase A1 gene. A 4.2 kb EcoRI fragment was isolated and sequenced. From nucleotide sequences and expression of various plasmids, two open reading frames (plaA and plaS) involved in efficient expression of phospholipase A1 in natural and recombinant host were identified. Extracellular phospholipase A1 activity was identified as the gene product of plaA encoding 321 amino acids with a predicted MW of 33,400. Analysis of the amino acid sequence revealed significant homology (around 70%) to phospholipase A1 of Serratia liquefaciens and Yersinia enterocolitica. The sequence, -Gly-X1-Ser-X2-Gly-, known as a lipase-specific consensus sequence was also found in the bacterial phospholipase A1. PlaS encoding a protein of 224 amino acids showed no enzymatic activity, but might be necessary for the efficient expression of phospholipase A1 in E. coli. To further improve the production of phospholipase A1 as a soluble and active form in E. coli, the effect of some parameters was examined. Surprisingly, a higher yield of soluble and active phospholipase A1 could be obtained under the combined conditions of a lower temperature, an enriched medium, and a lower-strength promoter.
ESTHER : Song_1999_J.Biotechnol_72_103
PubMedSearch : Song_1999_J.Biotechnol_72_103
PubMedID: 10406101
Gene_locus related to this paper: 9entr-PLAA